Showing results (251-260 of 396) with videos related to

Sort By:
Pageof 40
The Lancet. Oncology|June 9, 2017
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trialMichael A Davies, Philippe Saiag, Caroline Robert, et al.
Pigment Cell & Melanoma Research|August 13, 2014
Biology of advanced uveal melanoma and next steps for clinical therapeuticsJason J Luke, Pierre L Triozzi, Kyle C McKenna, et al.
The Lancet. Oncology|March 26, 2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialReinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1KCarolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2019
Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous MelanomaJiayi Yu, Junya Yan, Qian Guo, et al.
The Lancet. Oncology|September 17, 2018
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2021
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)Helen Gogas, Reinhard Dummer, Paolo A Ascierto, et al.
JCO Precision Oncology|February 20, 2026
Larotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1ENeal Akhave, Zihe Song, David S Hong, et al.
Cell Reports|April 22, 2014
Isolation and molecular characterization of circulating melanoma cellsXi Luo, Devarati Mitra, Ryan J Sullivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2025
Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131)Mohamed A Gouda, Filip Janku, Ying Yuan, et al.
Pageof 40